Heloterä Hanna, Arffman Martti, Sund Reijo, Keskimäki Ilmo, Kaarniranta Kai
Department of Ophthalmology, University of Eastern Finland, Kuopio, Finland.
Roche Oy, Espoo, Finland.
Acta Ophthalmol. 2024 Sep;102(6):643-652. doi: 10.1111/aos.16675. Epub 2024 Mar 24.
The worldwide prevalence of diabetes mellitus (DM) continues to increase. As DM is linked to various ophthalmological comorbidities, it is crucial to understand the incidence and the treatment patterns of these complications to minimise the treatment burden for the patient and the healthcare system. This study aims to evaluate the incidence and prevalence of diabetic macular oedema (DME) and proliferative diabetic retinopathy (PDR) and to analyse intravitreal (IVT) treatment patterns and responses in the Finnish population with diabetes.
A nationwide data register containing details of over 20-year-old individuals with diabetes was used in the analyses.
The incidence and prevalence of DME and PDR among the Finnish population with diabetes either declined or remained stable during 2007-2017 (Incidence rate: DME -40.8%, PDR -65.3%; prevalence rate: DME +4.7%, PDR -11.2%). During the same period, number of persons suffering from diabetes increased by +58.3%. The total number of IVT injections increased by 261.7%; the number of patients receiving IVT treatments increased by 133.6% from 2011 to 2017, reflecting changes in patient numbers in the ophthalmology departments. Furthermore, irrespective of the rising number of patients with diabetes, the numbers with visual impairment declined by 75.8% among DME and by 75.7% among PDR patients in 2007-2017.
Regardless of the considerable increase in the workload of ophthalmology departments, the healthcare system has been able to reduce both the age and sex standardised incidence of DME and PDR among the diabetic population suffering from a visual impairment associated with this disease.
全球糖尿病(DM)患病率持续上升。由于糖尿病与多种眼科合并症相关,了解这些并发症的发病率和治疗模式对于减轻患者和医疗系统的治疗负担至关重要。本研究旨在评估糖尿病性黄斑水肿(DME)和增殖性糖尿病视网膜病变(PDR)的发病率和患病率,并分析芬兰糖尿病患者群体的玻璃体内(IVT)治疗模式及反应。
分析中使用了一个包含20岁以上糖尿病患者详细信息的全国性数据登记册。
2007 - 2017年期间,芬兰糖尿病患者群体中DME和PDR的发病率和患病率要么下降,要么保持稳定(发病率:DME下降40.8%,PDR下降65.3%;患病率:DME上升4.7%,PDR下降11.2%)。同一时期,糖尿病患者人数增加了58.3%。IVT注射总数增加了261.7%;2011年至2017年接受IVT治疗的患者人数增加了133.6%,反映了眼科部门患者数量的变化。此外,尽管糖尿病患者数量不断增加,但在2007 - 2017年期间,DME患者中视力受损人数下降了75.8%,PDR患者中下降了75.7%。
尽管眼科部门的工作量大幅增加,但医疗系统已能够降低患有与该疾病相关视力损害的糖尿病患者群体中DME和PDR的年龄和性别标准化发病率。